These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 37972145)
1. Willingness to pay for antiretroviral therapy, viral load, and premium services; A contingent valuation survey of people living with HIV in southern Nigeria. Sanwo O; Iyamu I; Idemudia A; Badru T; Ekponimo S; Oqua D; Makinde OA; Aliyu GG; Kola-Jebutu A; Egwuagu-Pius J; Obiora-Okafo C; Bateganya M; Apera I; Pandey SR; Khamofu H PLoS One; 2023; 18(11):e0289507. PubMed ID: 37972145 [TBL] [Abstract][Full Text] [Related]
2. Willingness to pay for antiretroviral drugs among HIV and AIDS clients in south-east Nigeria. Mbachu C; Okoli C; Onwujekwe O; Enabulele F Health Expect; 2018 Feb; 21(1):270-278. PubMed ID: 28805985 [TBL] [Abstract][Full Text] [Related]
3. Co-financing for viral load monitoring during the course of antiretroviral therapy among patients with HIV/AIDS in Vietnam: A contingent valuation survey. Nguyen QL; Nguyen LH; Tran BX; Phan HT; Le HT; Nguyen HD; Tran TD; Do CD; Nguyen CM; Thuc VT; Latkin C; Zhang MW; Ho RC PLoS One; 2017; 12(2):e0172050. PubMed ID: 28199405 [TBL] [Abstract][Full Text] [Related]
4. Financial mobilization for antiretroviral therapy program: multi-level predictors of willingness to pay among patients with HIV/AIDS in Vietnam. Tran BX; Fleming M; Nguyen CT; Latkin CA AIDS Care; 2018 Dec; 30(12):1488-1497. PubMed ID: 30047280 [TBL] [Abstract][Full Text] [Related]
5. Assessing the willingness to pay for HIV counselling and testing service: a contingent valuation study in Lagos State, Nigeria. Adekunjo FO; Rasiah R; Dahlui M; Ng CW Afr J AIDS Res; 2020 Dec; 19(4):287-295. PubMed ID: 33337980 [TBL] [Abstract][Full Text] [Related]
6. Sustainability of Funding for HIV Treatment Services: A Cross-Sectional Survey of Patients' Willingness to Pay for Treatment Services in Nigeria. Durosinmi-Etti O; Fried B; Dubé K; Sylvia S; Greene S; Ikpeazu A; Nwala EK Glob Health Sci Pract; 2022 Apr; 10(2):. PubMed ID: 35487556 [TBL] [Abstract][Full Text] [Related]
7. Willingness to pay for community delivery of antiretroviral treatment in urban Tanzania: a cross-sectional survey. Geldsetzer P; Sauer A; Francis JM; Mboggo E; Lwezaula S; Sando D; Fawzi W; Ulenga N; Bärnighausen T Health Policy Plan; 2021 Feb; 35(10):1300-1308. PubMed ID: 33083837 [TBL] [Abstract][Full Text] [Related]
8. Willingness to pay for an mHealth anti-retroviral therapy adherence and information tool: Transitioning to sustainability, Call for life randomised study experience in Uganda. Naggirinya AB; Kyomugisha EL; Nabaggala MS; Nasasira B; Akirana J; Oseku E; Kiragga A; Castelnuovo B; King RL; Katabira E; Byonanebye DM; Lamorde M; Parkes-Ratanshi R BMC Med Inform Decis Mak; 2022 Feb; 22(1):52. PubMed ID: 35219309 [TBL] [Abstract][Full Text] [Related]
9. Distribution of antiretroviral therapy through private pharmacies and postal courier services during COVID-19 in Botswana: acceptability and reach of two out-of-facility individual differentiated service delivery models. Mpofu M; Moyo T; Gilbert M; Dikobe W; Nishimoto L; Katiko G; Batuka J; Satti H; Qambayot M; Mahler H; Kitso L; Marqusee H; Bateganya M J Int AIDS Soc; 2021 Oct; 24 Suppl 6(Suppl 6):e25814. PubMed ID: 34713589 [TBL] [Abstract][Full Text] [Related]
10. How do patients prefer specialized clinical pharmacy service to other prevention of mother-to-child transmission of human immunodeficiency virus services? An evaluation of their willingness to pay and willingness to accept choices and ratios. Isah A; Adibe MO; Abba A; Dim OF; Ekwuofu AA; Ma'aji HU; Ukwe CV; Udeogaranya PO; Okonta MJ J Clin Pharm Ther; 2021 Dec; 46(6):1695-1705. PubMed ID: 34448210 [TBL] [Abstract][Full Text] [Related]
11. Determinants of willingness to participate in health insurance amongst people living with HIV in a tertiary hospital in South-East Nigeria. Alo CN; Okedo-Alex IN; Akamike IC Niger Postgrad Med J; 2020; 27(3):196-201. PubMed ID: 32687119 [TBL] [Abstract][Full Text] [Related]
12. Differentiated service delivery models among PLHIV in Akwa Ibom and Cross River States, Nigeria during the COVID-19 pandemic: descriptive analysis of programmatic data. Sanwo O; Persaud NE; Nwaokoro P; Idemudia A; Akpan U; Toyo O; Imohi P; Badru T; Obiora-Okafo C; Uzochukwu CE; Aliu O; Olatunbosun K; Pandey SR; Khamofu H; Chiegil R; James E; Iyortim I; Oqua D; Bateganya M J Int AIDS Soc; 2021 Oct; 24 Suppl 6(Suppl 6):e25820. PubMed ID: 34713591 [TBL] [Abstract][Full Text] [Related]
13. Willingness to Pay for a Contributory Social Health Insurance Scheme: A Survey of Rural Residents in Akwa Ibom State, Nigeria. Akwaowo CD; Umoh I; Motilewa O; Akpan B; Umoh E; Frank E; Nna E; Okeke U; Onwujekwe OE Front Public Health; 2021; 9():654362. PubMed ID: 34222168 [No Abstract] [Full Text] [Related]
14. Decentralization of viral load testing to improve HIV care and treatment cascade in rural Tanzania: observational study from the Kilombero and Ulanga Antiretroviral Cohort. Mnzava D; Okuma J; Ndege R; Kimera N; Ntamatungiro A; Nyuri A; Byakuzana T; Abilahi F; Mayeka P; Temba E; Fanuel T; Glass TR; Klimkait T; Vanobberghen F; Weisser M; BMC Infect Dis; 2023 Apr; 23(1):222. PubMed ID: 37029356 [TBL] [Abstract][Full Text] [Related]
15. Willingness-to-Accept and Willingness-to-Pay Ratios of Prevention of Mother-to-Child Transmission Services in a Nigerian Hospital: A Cross-Sectional Contingent Valuation Study. Isah A; Adibe MO; Anosike C; Aluh DO; Onyekwelu PO; Okonta MJ; Ukwe CV Value Health Reg Issues; 2019 Sep; 19():112-121. PubMed ID: 31404819 [TBL] [Abstract][Full Text] [Related]
16. Optimizing community linkage to care and antiretroviral therapy Initiation: Lessons from the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) and their adaptation in Nigeria ART Surge. Jahun I; Said I; El-Imam I; Ehoche A; Dalhatu I; Yakubu A; Greby S; Bronson M; Brown K; Bamidele M; Boyd AT; Bachanas P; Dirlikov E; Agbakwuru C; Abutu A; Williams-Sherlock M; Onotu D; Odafe S; Williams DB; Bassey O; Ogbanufe O; Onyenuobi C; Adeola A; Meribe C; Efuntoye T; Fagbamigbe OJ; Fagbemi A; Ene U; Nguhemen T; Mgbakor I; Alagi M; Asaolu O; Oladipo A; Amafah J; Nzelu C; Dakum P; Mensah C; Aliyu A; Okonkwo P; Oyeledun B; Oko J; Ikpeazu A; Gambo A; Charurat M; Ellerbrock T; Aliyu S; Swaminathan M PLoS One; 2021; 16(9):e0257476. PubMed ID: 34543306 [TBL] [Abstract][Full Text] [Related]
17. Towards achieving the 90-90-90 HIV targets: results from the south African 2017 national HIV survey. Marinda E; Simbayi L; Zuma K; Zungu N; Moyo S; Kondlo L; Jooste S; Nadol P; Igumbor E; Dietrich C; Briggs-Hagen M BMC Public Health; 2020 Sep; 20(1):1375. PubMed ID: 32907565 [TBL] [Abstract][Full Text] [Related]
18. Changes in D-dimer after initiation of antiretroviral therapy in adults living with HIV in Kenya. Teasdale CA; Hernandez C; Zerbe A; Chege D; Hawken M; El-Sadr WM BMC Infect Dis; 2020 Jul; 20(1):508. PubMed ID: 32664854 [TBL] [Abstract][Full Text] [Related]
19. Willingness to Pay for HIV Prevention Commodities Among Key Population Groups in Nigeria. Durosinmi-Etti O; Nwala EK; Oki F; Ikpeazu A; Godwin E; Umoh P; Shaibu A; Ogundipe A; Kalaiwo A Glob Health Sci Pract; 2022 Oct; 10(5):. PubMed ID: 36316139 [TBL] [Abstract][Full Text] [Related]
20. High rates of loss to follow-up during the first year of pre-antiretroviral therapy for HIV patients at sites providing pre-ART care in Nigeria, 2004-2012. Agolory SG; Auld AF; Odafe S; Shiraishi RW; Dokubo EK; Swaminathan M; Dalhatu I; Onotu D; Abiri O; Debem H; Bashorun A; Ellerbrock TV PLoS One; 2017; 12(9):e0183823. PubMed ID: 28863160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]